<DOC>
	<DOCNO>NCT00004873</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat advanced stomach cancer . PURPOSE : Randomized phase II trial compare effectiveness different regimen combination chemotherapy treat patient advanced stomach cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy tolerability docetaxel , cisplatin , fluorouracil ( TCF ) versus docetaxel cisplatin ( TC ) versus epirubicin , cisplatin , fluorouracil ( ECF ) patient advance gastric carcinoma . - Compare time treatment failure , time progression , survival patient population treat regimen . - Compare quality life treatment period failure patient population . OUTLINE : This randomize , multicenter study . Patients stratify accord center , performance status ( 0 vs 1 ) , liver involvement ( yes v ) . Patients randomize one three treatment arm . - Arm I : Patients receive epirubicin IV bolus cisplatin IV 4 hour day 1 plus fluorouracil IV continuously day 1-21 . - Arm II : Patients receive docetaxel IV 1 hour cisplatin IV 4 hour day 1 . - Arm III : Patients receive docetaxel cisplatin arm II fluorouracil arm I . Treatment regimen repeat every 3 week 8 course absence disease progression unacceptable toxicity . Quality life assess randomization ; day 1 course 2 , 4 , 6 ; one month treatment failure . Patients complete response partial response follow monthly 3 month . PROJECTED ACCRUAL : Approximately 111 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastric carcinoma amenable curative surgery relapse primary surgical resection Locally advance disease ( i.e. , measurable locoregional lymph node ) OR Metastatic disease Bidimensionally measurable disease At least 10 mm X 20 mm chest xray physical examination At least 10 mm X 10 mm CT scan No CNS metastasis PATIENT CHARACTERISTICS : Age : 18 70 Performance status : 01 Life expectancy : Greater 12 week Hematopoietic : WBC count least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Alkaline phosphatase great 5 time ULN Renal : BUN normal Creatinine normal Creatinine clearance least 60 mL/min No severe hypercalcemia Cardiovascular : No unstable cardiac disease require treatment No congestive heart failure No angina pectoris even medically control No significant arrhythmias No prior myocardial infarction unless ejection fraction least 50 % MUGA scan echocardiogram Neurologic : No prior significant neurologic psychiatric disorder , include psychotic disorder , dementia seizure would preclude study No peripheral neuropathy origin ( alcohol , etc . ) great grade 1 Other : Fertile patient must use adequate contraception No prior malignancy except basal cell skin cancer adequately treat carcinoma situ cervix No active uncontrolled infection No serious illness medical condition would preclude study participation No contraindication corticosteroid use PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior palliative chemotherapy At least 12 month since prior adjuvant neoadjuvant chemotherapy No prior taxanes Prior fluorouracil allow bolus form Prior cumulative dose adjuvant neoadjuvant cisplatin great 300 mg/m2 Endocrine therapy : Prior concurrent prednisone ( equivalent ) allow prophylaxis , acute hypersensitivity reaction , chronic therapy ( great 6 month ) dose great 20 mg Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent experimental drug No concurrent anticancer therapy At least 30 day since treatment prior clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
</DOC>